Clinical Trial Update: A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating GFH925 in combination with cetuximab for previously untreated advanced non-small cell lung cancer with a KRAS G12C mutation has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• GFH925

Snippet

Sponsor: Genfleet Therapeutics (Shanghai) Inc. | Conditions: Advance Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED